| Characteristic | Share of respondents |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Source
Source
Release date
February 2026
More information
Region
Australia, Canada, Asia, Europe, United States
Survey time period
July to August 2025
Number of respondents
150 executives
Special properties
Respondents from large companies: n=61, from small/mid: n=86
Method of interview
Panel survey
Supplementary notes
Survey question: "What are the primary concerns or challenges that prevent, limit, or slow the integration of AI/ML into your drug development processes? "
Citation formats
